Thomas Gunderson Sells 9,624 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Thomas Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TransMedics Group Stock Up 7.6%

TransMedics Group stock opened at $78.79 on Friday. The company’s 50-day moving average price is $84.00 and its two-hundred day moving average price is $113.03. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.72 billion, a P/E ratio of 17.91 and a beta of 1.91. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. As a group, analysts expect that TransMedics Group, Inc. will post 1.98 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its stake in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares during the last quarter. Wellington Management Group LLP boosted its stake in TransMedics Group by 100.5% in the fourth quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock valued at $52,713,000 after buying an additional 217,180 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in TransMedics Group by 43.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after buying an additional 171,810 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in TransMedics Group by 11.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after acquiring an additional 113,817 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMDX. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Piper Sandler cut their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Stifel Nicolaus increased their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday. Canaccord Genuity Group lowered their target price on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $134.50.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.